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The authors reply: Eskazan speculates that a 
regimen using daunorubicin at a dose of 90 mg 
per square meter (with or without midostaurin) 
would lead to superior outcomes as compared 
with the regimen of daunorubicin at a dose of 
60 mg per square meter plus midostaurin that 
was used in the CALGB 10603 trial. However, at 
the time that the trial was designed, neither the 
results showing the superiority of induction with 
daunorubicin at a dose of 90 mg per square meter 
as compared with 45 mg per square meter in 
FLT3-mutated AML1 nor those suggesting that the 
higher dose of this anthracycline might be better 
than 60 mg per square meter in FLT3-mutated 
AML2 were available. These cited data are derived 
from retrospective analyses that were not powered 
to show significant differences. With all the ca-
veats involved in comparing one trial with an-
other, the results with the induction of daunoru-
bicin at a dose of 60 mg per square meter plus 
midostaurin in the CALGB 10603 trial were, if 
anything, slightly better than the results with a 
dose of 90 mg per square meter in the Eastern 
Cooperative Oncology Group 1900 (E1900) trial1 
and the U.K. Medical Research Council AML17 
trial.2
A detailed analysis of the effect of NPM1 co-
mutations on the outcome in each group of the 
CALGB 10603 trial is of interest. In the prelimi-
nary trial, concurrent administration of midostau-
rin and chemotherapy had neither a better side-
effect profile nor better efficacy3 than the 
sequential schedule used in the CALGB 10603 
trial. However, we agree that further exploration 
of midostaurin schedules and effects on target 
inhibition are warranted.
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Acute Respiratory Distress Syndrome
To the Editor: In their review of the acute re-
spiratory distress syndrome (ARDS) (Aug. 10 
issue),1 Thompson et al. recommend that pa-
tients be placed in the prone position when the 
ratio of the partial pressure of arterial oxygen 
to the fraction of inspired oxygen (Pao2:Fio2) is 
less than 120 mm Hg. However, the guidelines 
for the mechanical ventilation of patients with 
ARDS2 recommend this strategy for patients 
with severe ARDS, which the guidelines define 
as a Pao2:Fio2 of less than 100 mm Hg. Further-
more, one of the inclusion criteria for a trial 
that showed a decrease in mortality with this 
maneuver was a Pao2:Fio2 of 150 mm Hg or less.
3 
In regard to neuromuscular blocking agents, 
Thompson et al. recommend the use of such 
drugs when the Pao2:Fio2 is less than 150 mm Hg. 
This statement is in agreement with the guide-
lines for the use of neuromuscular blocking 
agents in critically ill patients,4 but the trial 
conducted by Papazian et al., which is cited by 
the authors, showed that these agents had a ben-
eficial effect on survival at 90 days for patients 
with a baseline Pao2:Fio2 of less than 120 mm Hg.
5 
This finding has important clinical relevance, 
since the thresholds defined for the initiation 
of interventions, if unclear, may lead to inappro-
priate exposure to these interventions or delays 
in their withdrawal, either of which may put 
patients at risk.
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To the Editor: Thompson et al. do not include 
drugs as a possible trigger for ARDS. For exam-
ple, some of the drugs used to treat cancer, such 
as cytarabine, gefitinib, gemcitabine, vinblastine, 
and vincristine, are a well-recognized cause of 
ARDS.1,2 Amiodarone, infliximab, nitrofurantoin, 
verapamil, narcotics, and overdoses of salicylates 
have also been implicated as causes of ARDS. 
Overall, drugs are implicated in approximately 
13% of patients with ARDS in the absence of 
other identified precipitating factors.3 Although 
for most drugs the exact mechanism of pulmo-
nary toxicity has not been elucidated, direct, drug-
induced damage of pulmonary vascular endothe-
lial cells and alveolar epithelial cells has been 
suggested.2 Drug-induced ARDS should be con-
sidered if the cause of lung injury is not evident.4 
The diagnosis of drug-induced ARDS is based on 
a history of drug exposure, with a temporal rela-
tion between the introduction of the drug and 
the onset of symptoms, and on the exclusion of 
other causes of acute lung injury. Treatment is 
based on timely withdrawal of the offending 
drug and the provision of supportive measures.
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The authors reply: The official clinical practice 
guideline of the American Thoracic Society, the 
European Society of Intensive Care Medicine, and 
the Society of Critical Care Medicine strongly rec-
ommends the use of the prone position in pa-
tients with a Pao2:Fio2 of 100 mm Hg or less; this 
approach is supported by data showing a lower 
risk of death, as compared with the use of me-
chanical ventilation in the supine position. How-
ever, there was a lack of consensus regarding the 
use of the prone position in patients with a 
Pao2:Fio2 of 101 to 150 mm Hg owing to a “lower 
confidence in the balance between desirable as 
compared with undesirable outcomes in this sub-
group of patients.”1
As we noted in our review, a recent global 
survey of more than 29,000 patients who received 
mechanical ventilation showed that ARDS, even 
in its severest form, is underrecognized.2 The 
prone position was used in only 16.3% of patients 
recognized by clinicians as having severe ARDS 
(patients with a Pao2:Fio2 of less than 100 mm Hg), 
the subset in which the evidence of benefit is 
strongest and for which we have consensus. Ac-
cordingly, increased recognition of ARDS and 
increased use of ventilation with patients in the 
prone position in the subset of patients with se-
vere disease should be high priorities.1,2 We agree 
with Jaramillo-Rocha that thresholds should also 
guide the decision to change from the prone 
to the supine position at a Pao2:Fio2 of at least 
150 mm Hg, measured approximately 4 hours 
after returning to ventilation in the supine posi-
tion, with a positive end-expiratory pressure of 
10 cm of water or less and an Fio2 of 0.6 or less, 
as reported by Guérin et al.3
We agree that drug-induced lung disease should 
be considered when assessing a patient with ARDS 
and note this in Table 3 of our article, available 
at NEJM.org. We thank Ben Salem for drawing 
attention to this important clinical caveat.
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ISSCR 2018
The annual meeting of the International Society for Stem 
Cell Research will be held in Melbourne, Australia, June 20–23.
Contact the International Society for Stem Cell Research, 
5215 Old Orchard Rd., Suite 270, Skokie, IL 60077; or call (224) 
592-5700; or see http://www.isscr.org.
ONCOLOGY DRUG DEVELOPMENT IN PRACTICE
The course will be offered in Amsterdam, Nov. 22–24.
Contact Congress by design, P.O. Box 77, 3480 DB Harmelen, 
the Netherlands; or call (31) 88 08 98 101; or e-mail oddp@
congressbydesign.com; or see http://congressbydesign.com/oddp.
NEPHROLOGY 2018
The course will be offered in Boston, March 18–23. It is 
jointly sponsored by Harvard Medical School and Beth Israel 
Deaconess Medical Center.
Contact Harvard Medical School Department of Continuing 
Education, P.O. Box 825, Boston, MA 02117-0825; or call (617) 
384-8600; or e-mail ceprograms@hms.harvard.edu; or see 
http://www.nephrologyboston.com.
THOMAS L. PETTY ASPEN LUNG CONFERENCE
The 61st Annual Meeting, entitled “Translating Resilience 
and Pathogenesis to Personalized Therapy for COPD,” will be 
held in Aspen, CO, June 6–9. Deadline for submission of ab-
stracts is Feb. 14.
Contact Dr. R. William Vandivier, c/o Jeanne Cleary, Thomas 
L. Petty Aspen Lung Conference, P.O. Box 1622, Parker, CO 80134; 
or call (303) 358-2797; or e-mail Jeanne.Cleary@ucdenver.edu; 
or see http://www.aspenlungconference.org.
CARS 2018
The congress will be held in Berlin, June 20–23. Deadline 
for submission of abstracts and papers is Jan. 10.
Contact Mrs. Franziska Schweikert, CARS Conference Office, 
Klettgaustr. 20, 79790 Kuessaberg, Germany; or call (49) 7742-922 
434; or e-mail office@cars-int.org; or see http://www.cars-int.org.
UPDATE IN INTERNAL MEDICINE 2017
The course will be offered in Boston, Dec. 3–9. It is jointly 
presented by Harvard Medical School and Beth Israel Deaconess 
Medical Center.
Contact the Department of Continuing Education, Harvard 
Medical School, P.O. Box 825, Boston, MA 02117-0825; or call 
617-384-8600; or e-mail ceprograms@hms.harvard.edu; or see 
http://www.updateinternalmedicine.com.
ROOSEVELT ISLAND HISTORICAL SOCIETY
The Roosevelt Island Historical Society is seeking physi-
cians who worked on the New York City island as students, 
interns, and residents to learn about their experiences. The is-
land was known as Welfare Island until 1973.
Contact Judith Berdy, Roosevelt Island Historical Society, 
531 Main St., Roosevelt Island, NY 10044; or call (212) 688-4836; 
or e-mail rooseveltislandhistory@usa.com.
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